Main Article Content
dexmedetomidine, inflammation, barrier damage, RhoA/ROCK signaling pathway, ulcerative colitis
Objective: This study investigated the role of dexmedetomidine (DEX) in dextran sulfate sodium (DSS)-induced NCM460 cells.
Material and Methods: The viability and apoptosis of NCM460 cells treated with DEX with or without DSS were detected by CCK-8 and terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling (TUNEL) assay. The level of inflammatory factors and expression of inflammation-related proteins, tight junction proteins and Ras homolog gene family, member A/Rho-associated coiled-coil containing protein kinase (RhoA/ROCK) signaling-related proteins in NCM460 cells treated with DEX and/or U46619 (RhoA/ROCK agonist) and/or DSS were detected by the respective enzyme-linked immunosorbent assay (ELISA) kits and Western blot analysis. The permeability of NCM460 monolayers was examined with transepithelial electrical resistance (TEER) assay.
Results: DEX had no effect on NCM460 cell viability. However, DEX improved the viability and barrier damage and suppressed the apoptosis and inflammation of DSS-induced NCM460 cells. Correspondingly, the expression of inflammation-related proteins was reduced and the expression of tight junction proteins was increased in DSS-induced NCM460 cells after treatment with DEX. In addition, RhoA/ROCK signaling was activated in NCM460 cells induced by DSS, which was suppressed by DEX. The protective effects of DEX on DSS-indued NCM460 cells were reversed by U46619.
Conclusion: DEX improved viability and barrier damage while suppressed apoptosis and inflammation in DSS-indued NCM460 cells by inhibiting RhoA/ROCK signaling pathway.
2. Adams SM and Bornemann PH. Ulcerative colitis. Am Family Physician. 2013;87:699–705.
3. Eisenstein M. Ulcerative colitis: Towards remission. Nature. 2018;563:S33. 10.1038/d41586-018-07276-2
4. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: A systematic review. AmJ Gastroenterol. 2009;104:2100–9. 10.1038/ajg.2009.190
5. Weerink MAS, Struys M, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2017;56:893–913. 10.1007/s40262-017-0507-7
6. Yang J, Wu Y, Xu Y, Jia J, Xi W, Deng H, et al. Dexmedetomidine resists intestinal ischemia-reperfusion injury by inhibiting TLR4/MyD88/NF-κB signaling. J Surg Res. 2021;260:350–8. 10.1016/j.jss.2020.11.041
7. Qin C, Jiang Y, Chen X, Bian Y, Wang Y, Xie K, et al. Dexmedetomidine protects against burn-induced intestinal barrier injury via the MLCK/p-MLC signalling pathway. Burns J Int Soc Burn Inj. 2021;47:1576–85. 10.1016/j.burns.2021.01.017
8. Chen Y, Miao L, Yao Y, Wu W, Wu X, Gong C, et al. Dexmedetomidine ameliorates CLP-induced rat intestinal injury via inhibition of inflammation. Mediat Inflamm. 2015;2015:918361. 10.1155/2015/918361
9. Chen CJ, Xiao P, Chen Y, Fang R. Selenium deficiency affects uterine smooth muscle contraction through regulation of the RhoA/ROCK signalling pathway in mice. Biol Trace Elem Res. 2019;192:277–86. 10.1007/s12011-019-01677-8
10. Knipe RS, Probst CK, Lagares D, Franklin A, Spinney JJ, Brazee PL, et al. The Rho kinase isoforms ROCK1 and ROCK2 each contribute to the development of experimental pulmonary fibrosis. Am J Resp Cell Mol Biol. 2018;58:471–81. 10.1165/rcmb.2017-0075OC
11. Yang W, Zhou G, Yu T, Chen L, Yu L, Guo Y, et al. Critical role of ROCK2 activity in facilitating mucosal CD4(+) T cell activation in inflammatory bowel disease. J Autoimmun. 2018;89:125–38. 10.1016/j.jaut.2017.12.009
12. Zou Y, Ma L, Zhao Y, Zhang S, Zhou C, Cai Y. Inhibition of Rho kinase protects against colitis in mice by attenuating intestinal epithelial barrier dysfunction via MLC and the NF-κB pathway. Int J Mol Med. 2018;41:430–8. 10.3892/ijmm.2017.3197
13. Kang W, Shang L, Wang T, Liu H, Ge S. Rho-kinase inhibitor Y-27632 downregulates LPS-induced IL-6 and IL-8 production via blocking p38 MAPK and NF-κB pathways in human gingival fibroblasts. J Periodontol. 2018;89:883–93. 10.1002/JPER.17-0571
14. Wang S, Lin Y, Yuan X, Li F, Guo L, Wu B. REV-ERBα integrates colon clock with experimental colitis through regulation of NF-κB/NLRP3 axis. Nature Communicat. 2018;9:4246. 10.1038/s41467-018-06568-5
15. Hu T, Lin Q, Guo T, Yang T, Zhou W, Deng X, et al. Polysaccharide isolated from Phellinus linteus mycelia exerts anti-inflammatory effects via MAPK and PPAR signaling pathways. Carbohyd Polym. 2018;200:487–97. 10.1016/j.carbpol.2018.08.021
16. Sun T, Gong Q, Wu Y, Shen Z, Zhang Y, Ge S, et al. Dexmedetomidine alleviates cardiomyocyte apoptosis and cardiac dysfunction may be associated with inhibition of RhoA/ROCK pathway in mice with myocardial infarction. Naunyn-Schmiedeberg’s Arch Pharmacol. 2021;394:1569–77. 10.1007/s00210-021-02082-6
17. Wang Y, Chen H, Chen Q, Jiao FZ, Zhang WB, Gong ZJ. The protective mechanism of CAY10683 on intestinal mucosal barrier in acute liver failure through LPS/TLR4/MyD88 pathway. Mediat Inflamm. 2018;2018:7859601. 10.1155/2018/7859601
18. Zizzo MG, Caldara G, Bellanca A, Nuzzo D, Di Carlo M, Serio R. Preventive effects of guanosine on intestinal inflammation in 2,4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rats. Inflammopharmacol. 2019;27:349–59. 10.1007/s10787-018-0506-9
19. Bevivino G, Monteleone G. Advances in understanding the role of cytokines in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2018;12:907–15. 10.1080/17474124.2018.1503053
20. El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am J Gastroenterol. 2006;101:311–7. 10.1111/j.1572-0241.2006.00384.x
21. El-Gowelli HM, Saad EI, Abdel-Galil AG, Ibrahim ER. Co-administration of α-lipoic acid and cyclosporine aggravates colon ulceration of acetic acid-induced ulcerative colitis via facilitation of NO/COX-2/miR-210 cascade. Toxicol Appl Pharmacol. 2015;288:300–12. 10.1016/j.taap.2015.08.002
22. Yu L, Yan J, Sun Z. D-limonene exhibits anti-inflammatory and antioxidant properties in an ulcerative colitis rat model via regulation of iNOS, COX-2, PGE2 and ERK signaling pathways. Mol Med Rep. 2017;15:2339–46. 10.3892/mmr.2017.6241
23. Guo Y, Wu X, Wu Q, Lu Y, Shi J, Chen X. Dihydrotanshinone I, a natural product, ameliorates DSS-induced experimental ulcerative colitis in mice. Toxicol Appl Pharmacol. 2018;344:35–45. 10.1016/j.taap.2018.02.018
24. Heng-Guang Z. Effects of tetrandrine on COX-2/PGE_2,iNOS/NO expression in LPS-stimulated RAW264. 7 cells.J China Pharm Univ. 2011;42:141–4.
25. Li C, Cai YY, Yan ZX. Brain-derived neurotrophic factor preserves intestinal mucosal barrier function and alters gut microbiota in mice. Kaohsiung J Med Sci. 2018;34:134–41. 10.1016/j.kjms.2017.11.002
26. Chen S, Zuo S, Zhu J, Yue T, Bu D, Wang X, et al. Decreased expression of cystathionine β-synthase exacerbates intestinal barrier injury in ulcerative colitis. J Crohn’s Colitis. 2019;13:1067–80. 10.1093/ecco-jcc/jjz027
27. Gai L, Chu L, Xia R, Chen Q, Sun X. Barbaloin attenuates mucosal damage in experimental models of rat colitis by regulating inflammation and the AMPK signaling pathway. Med Sci Monitor Int Med J Exp Clin Res. 2019;25:10045–56. 10.12659/MSM.918935
28. Wang J, Zhang C, Guo C, Li X. Chitosan ameliorates DSS-induced ulcerative colitis mice by enhancing intestinal barrier function and improving microflora. Int J Mol Sci. 2019;20:5751. 10.3390/ijms20225751
29. Al-Shboul O. The role of the RhoA/ROCK pathway in gender-dependent differences in gastric smooth muscle contraction. J Physiol Sci (JPS). 2016;66:85–92. 10.1007/s12576-015-0400-9
30. Del Re DP, Miyamoto S, Brown JH. RhoA/Rho kinase up-regulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis. J Biol Chem. 2007;282:8069–78. 10.1074/jbc.M604298200
31. Zheng X, Mai L, Wang T, Xu Y, Su Z, Chen J, et al. Brusatol-enriched brucea javanica oil ameliorated dextran sulfate sodium-induced colitis in mice: Involvement of NF-κB and RhoA/ROCK signaling pathways. BioMed Res Int. 2021;2021:5561221. 10.1155/2021/5561221
32. Wang Y, Shou Z, Fan H, Xu M, Chen Q, Tang Q, et al. Protective effects of oxymatrine against DSS-induced acute intestinal inflammation in mice via blocking the RhoA/ROCK signaling pathway. Biosci Rep. 2019;39:BSR20182297. 10.1042/BSR20182297